Evidence map›Paper›PMID 42334082›Full record

ArticleEuropean journal of immunology2026

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

Caroline Diener, Rebecca Urschel, Saskia Bronder, Candida Guckelmus, Johannes Eckel, Franziska Hielscher, Denisa Bojkova, Sandra Ciesek, Marek Widera, Tina Schmidt and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Caroline DienerDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Rebecca UrschelDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Saskia BronderDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Candida GuckelmusDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Johannes EckelDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Franziska HielscherDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Denisa BojkovaInstitute For Medical Virology, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.
Sandra CiesekInstitute For Medical Virology, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.
Marek WideraInstitute For Medical Virology, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.
Tina SchmidtDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.
Martina SesterDepartment of Transplant and Infection Immunology, PharmaScienceHub, Saarland University, Homburg, Germany.

Funding

Deutsche Forschungsgemeinschaft DFG INST 256/567-1 FUGGDr. Rolf M. Schwiete Stiftung 2023-047German Federal Ministry of Education and Research COVIM 2.0German Federal Ministry of Education and Research FKZ 01KX2121
6 · The paper itself

Abstract

The continuous evolution of SARS-CoV-2 raises concerns about immune escape from preexisting immunity. The monovalent JN.1adapted mRNA vaccine was developed to better match circulating variants, yet data on its ability to induce and broaden humoral and cellular immunity in individuals with or without prior infection remain limited. We recruited 37 immunocompetent adults before and two weeks after JN.1 vaccination to assess vaccine-induced immunity. Spike-specific CD4 and CD8 T cells were quantified following stimulation with spike-derived peptides from the parental strain, XBB.1.5, and JN.1, and their CTLA-4 expression and cytokine profiles were analyzed by flow cytometry. Spike-specific IgG and neutralizing activity against authentic parental, XBB.1.5, JN.1, and KP.3.1.1 isolates were also measured. JN.1 vaccination significantly increased spike-specific CD4

Indexed as

COVID-19COVID-19 VaccinesImmunity, CellularImmunity, HumoralSARS-CoV-2AdultAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesFemaleHumansImmunoglobulin GMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCytokinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CD4 T cellCD8 T cellcross‐reactivityJN.1 vaccinationomicron JN.1SARS‐CoV‐2

Identifiers

PMID42334082
PMCPMC13288449

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.